These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9001898)

  • 1. The renoprotective action of angiotensin-converting enzyme inhibitors in diabetes.
    Ruggenenti P; Remuzzi G
    Exp Nephrol; 1996; 4 Suppl 1():53-60. PubMed ID: 9001898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis of diabetic nephropathy: how to improve the outcome.
    Remuzzi G; Ruggenenti P
    Diabetes Res Clin Pract; 1998 Apr; 39 Suppl():S49-53. PubMed ID: 9649960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.
    Cooper ME
    J Hypertens Suppl; 1996 Dec; 14(6):S11-4. PubMed ID: 9023709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal protection in essential hypertension: how do angiotensin-converting enzyme inhibitors compare with calcium antagonists?
    Bauer JH; Reams GP
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S80-7. PubMed ID: 16989071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibitors in diabetes: effect on the kidney and on blood pressure.
    Björck S; Aurell M
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S59-63. PubMed ID: 16989067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controversies on the prevention of diabetic nephropathy.
    Chiarelli F; Verrotti A; Basciani F; di Ricco L; Sabatino G; Morgese G
    J Pediatr Endocrinol Metab; 1998 Apr; 11 Suppl 2():365-9. PubMed ID: 9642666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
    Crook ED; Preddie DC
    Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB
    Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Angiotensin II type-1-receptor antagonists from the viewpoint of nephrology].
    Hauser AC; Hörl WH
    Wien Med Wochenschr; 2001; 151(7-8):160-4. PubMed ID: 11450164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB; Britton ML
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Renal side effects of angiotensin converting enzyme inhibitors].
    Schmidt A; Mayer G
    Wien Med Wochenschr; 1996; 146(16):454-6. PubMed ID: 9036683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prediction, screening and treatment of renal complications of diabetes].
    Marre M; Larger E
    Rev Prat; 2001 Oct; 51(16):1769-75. PubMed ID: 11795120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes, nephropathy, and the renin system.
    Hollenberg NK
    J Hypertens Suppl; 2006 Mar; 24(1):S81-7. PubMed ID: 16601578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACE inhibitor intervention in Type 1 diabetes with low grade microalbuminuria.
    Poulsen PL
    J Renin Angiotensin Aldosterone Syst; 2003 Mar; 4(1):17-26. PubMed ID: 12692749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural history of early diabetic nephropathy: what are the effects of therapeutic intervention? Melbourne Diabetic Nephropathy Study Group.
    Jerums G; Allen TJ; Gilbert RE; Hammond J; Cooper ME; Campbell DJ; Raffaele J
    J Diabetes Complications; 1995; 9(4):308-14. PubMed ID: 8573754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glomerular protein trafficking and progression of renal disease to terminal uremia.
    Benigni A; Remuzzi G
    Semin Nephrol; 1996 May; 16(3):151-9. PubMed ID: 8734458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment.
    Parving HH
    Diabetologia; 1998 Jul; 41(7):745-59. PubMed ID: 9686914
    [No Abstract]   [Full Text] [Related]  

  • 20. Renal function changes in diabetes.
    Mogensen CE
    Diabetes; 1976; 25(2 SUPPL):872-9. PubMed ID: 971791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.